Invivyd, Inc.

NASDAQ:IVVD

Biotechnology

Healthcare
$0.47 +4.16%

+$0.04 today

Market cap
$138.68M
Beta
0.63
P/E (TTM)
-3.9
EPS (TTM)
-$0.25
52W Low $0.48High $3.07

Volume 6.71M

Average 3.62M

IVVD Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Invivyd, Inc.NASDAQ: IVVD

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 309.67M shares rose 158.3% year over year, ahead of the +61.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 79.8% from the prior quarter. Over 3 fiscal years it compounded at +16.7% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +158.3% holds above the trailing-twelve-month pace of +61.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
309.67M+79.8% QoQ
Last fiscal yearDec 2025
172.21M+45.3% YoY
LTMMar 2026
193.02M+61.8% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+158.3%——
1 year+45.3%——
3-year CAGR+16.7%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
172.21M USD
Year-over-year change
+45.3%
4-year CAGR
+11.7%

Weighted Avg Shares vs competitors

How IVVD compares with its peers on the latest reported figures

  • IVVD's LTM Mar 2026 weighted avg shares of 193.02M shares is the 2nd highest of the 10 companies compared; the peer median is 89.2M shares.
  • Its year-over-year change of +61.8% is the 3rd highest of 9, against a peer median of +45.5%.
  • Over three fiscal years its annual growth of +16.7% compares with a peer median of +20.6%.
IVVD Competitors Peer median
Weighted Avg Shares for IVVD and competitors
Company Period LTM YoY 3-year CAGR
SGMOSangamo Therapeutics, Inc.LTM Mar 2026322.14M +52.9%+22.0%
IVVDInvivyd, Inc.LTM Mar 2026193.02M +61.8%+16.7%
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026179.3M +96.8%+77.8%
OABIOmniAb, Inc.LTM Mar 2026119.25M +15.1%+10.0%
CCCCC4 Therapeutics, Inc.LTM Mar 202696.61M +38.1%+19.3%
CDXSCodexis, Inc.LTM Mar 202689.2M +16.6%+10.1%
TARAProtara Therapeutics, Inc.LTM Mar 202643.36M +56.7%+56.1%
OBIOOrchestra BioMed Holdings, Inc.LTM Mar 202638.39M +2.6%+14.7%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 202632.26M +85.3%+76.5%
NTHINeonc Technologies Holdings, Inc.LTM Mar 202620.19M ——
Peer median (excluding IVVD) 89.2M+45.5%+20.6%

Competitors are the stored peer set for IVVD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00025.38M53.43M
Cost of Revenue0001.62M3.75M
Gross Profit00023.77M49.68M
Gross Margin———93.6%93.0%
Research & Development182.89M179.21M158.66M137.25M38.31M
Selling, General & Admin36.52M47.04M49.13M63.39M66.93M
Operating Expenses226.91M248.03M212.76M200.64M105.24M
Depreciation & Amortization1K462K2.03M3.11M2.11M
EBITDA(219.41M)(225.8M)(205.76M)(166.81M)(50.38M)
EBITDA Margin———-657.2%-94.3%
Operating Income(226.91M)(248.03M)(212.76M)(176.88M)(55.56M)
Operating Margin———-696.8%-104.0%
Interest Income06.71M06.95M0
Interest Expense043.08M000
Other Income / Expenses118K6.71M14.12M6.95M3.07M
Income Before Tax(226.79M)(241.32M)(198.64M)(169.93M)(52.49M)
Pre-Tax Margin———-669.4%-98.2%
Income Tax Expense00000
Net Income(226.79M)(241.32M)(198.64M)(169.93M)(52.49M)
Net Margin———-669.4%-98.2%
EPS (Basic)(2.11)(2.17)(1.81)(1.43)(0.30)
EPS (Diluted)(2.11)(2.17)(1.81)(1.43)(0.30)
Weighted Avg Shares110.78M108.27M109.53M118.56M172.21M
Weighted Avg Shares (Diluted)110.78M108.27M109.53M118.56M172.21M

Invivyd, Inc.

NASDAQ:IVVD

Intrinsic Alpha fair value

Locked

Current Price

$0.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.